Phio Pharmaceuticals (United States)
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Phio Pharmaceuticals (United States), United States, covering academic research published from 2009 to 2024. Read More.
Open Access Percentage
51%
Total
Publications
63
Total Open
Publications
32
Total
Citations
913
Open Access
Percentage
51%
Total
Publications
63
Total Open
Publications
32
Total
Citations
913
Breakdown
Publisher Open
39%
Both
10%
Other Platform Open
1%
Closed
50%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 20%
6
Hybrid 40%
12
No Guarantees 40%
12
Other Platform Open
Domain 71%
5
Other Internet 29%
2
Institution 0%
0
Preprint 0%
0
Public 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 5 |
DOI | Other Internet | 2 |